Geron Corporation (Nasdaq: GERN) today announced that an abstract describing clinical data regarding the telomerase inhibitor imetelstat has been selected ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE